Texas City, TX, United States of America

Amarnath Natarajan


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2010-2013

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Amarnath Natarajan: Innovator in Translation Inhibition

Introduction

Amarnath Natarajan is a distinguished inventor based in Texas City, TX. He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit translation initiation. With a total of six patents to his name, Natarajan's work has the potential to impact various medical applications.

Latest Patents

Natarajan's latest patents include innovative compositions and methods for inhibiting translation using 3-(5-tert-Butyl-2-Hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and its derivatives. These patents describe compositions, methods, and kits for treating cellular proliferative disorders, non-proliferative degenerative disorders, viral infections, and disorders associated with viral infections. His research focuses on the use of 3-(5-tert-butyl-2-hydroxy-phenyl)-3-phenyl-1,3-dihydro-indol-2-one and its derivatives as effective therapeutic agents.

Career Highlights

Amarnath Natarajan is affiliated with Harvard College, where he continues to advance his research in the field of biochemistry. His work has garnered attention for its potential applications in treating various health conditions. Natarajan's innovative approach to translation inhibition has positioned him as a key figure in his area of expertise.

Collaborations

Natarajan has collaborated with notable colleagues, including José A Halperin and Yun-Hua Fan. These partnerships have contributed to the advancement of his research and the development of new therapeutic strategies.

Conclusion

Amarnath Natarajan is a prominent inventor whose work in translation inhibition holds promise for addressing significant medical challenges. His contributions to the field are marked by a commitment to innovation and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…